Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.

Journal of surgical oncology - 1 Nov 2011

Lin Jen-Kou, Lin An-Jen, Lin Chun-Chi, Lan Yuan-Tzu, Yang Shung-Haur, Li Anna Fen-Yau, Chang Shih-Ching

Abstract excerpt

PURPOSE: This study was designed to analyze the impacts of status of EGFR-associated genes on the outcome of chemo-refractory mCRC patients using cetuximab. MATERIALS AND METHODS: We collected samples from 42 metastatic CRC patients refractory to FOLFOX or FOLFIRI. Mutation profiles of KRAS, BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Irinotecan

Share to Lymphatic Metastasis

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Salvage Therapy

Source

Identifiers

PMID: 21671463
DOI: 10.1002/jso.21993

Genes

EGFR
KRAS
PTEN
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21671463-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.PMID 21671463Read ↗

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Semantic proximity Read ↗

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer.Semantic proximity Read ↗

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.Semantic proximity Read ↗

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.Semantic proximity Read ↗

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.Semantic proximity Read ↗

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.Semantic proximity Read ↗

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Semantic proximity Read ↗

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.Semantic proximity Read ↗

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.